Metraipolis › archive › dc_e4b392018032
Antagonizing NRG1-ERBB4 signaling pathway with spironolactone for the treatment of schizophrenia: results of a randomized controlled drug repositioning… — Europe PMC PMID:42303794
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42303794
- DOI
- 10.1038/s43856-[numero omesso]-3
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-19T09:21:40.473Z
- SHA-256 of the archived text
12c9f400bb6a93ffcb2c5c91a9163c56aab5dc7dbec35e5f620d8cda4063602a- Stable URL of this page
https://metraipolis.com/documento/dc_e4b392018032
How to cite
Antagonizing NRG1-ERBB4 signaling pathway with spironolactone for the treatment of schizophrenia: results of a randomized controlled drug repositioning… — Europe PMC PMID:42303794 — Europe PMC (en), https://europepmc.org/article/MED/42303794 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_e4b392018032 (Metraipolis archive dc_e4b392018032, sha256 12c9f400bb6a93ffcb2c5c91a9163c56aab5dc7dbec35e5f620d8cda4063602a)
BibTeX
@misc{dce4b392018032,
title = {Antagonizing NRG1-ERBB4 signaling pathway with spironolactone for the treatment of schizophrenia: results of a randomized controlled drug repositioning… — Europe PMC PMID:42303794},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42303794},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_e4b392018032; sha256 12c9f400bb6a93ffcb2c5c91a9163c56aab5dc7dbec35e5f620d8cda4063602a},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42303794. Agents can read the archived copy with the MCP tool read_document.